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While many aspects of blood production are now well understood, the spatial organization 
of myeloid differentiation in the bone marrow (BM) remains unknown. Here, we use 
imaging to track granulocyte/macrophage progenitor (GMP) behavior during emergency 
and leukemic myelopoiesis. At steady state, we find individual GMPs scattered throughout 
the BM. During regeneration, we observe expanding GMP patches forming defined GMP 
clusters, which, in turn, locally differentiate into granulocytes. We describe how the timed 
release of important BM niche signals (SCF, IL-1β, G-CSF, TGF-β, CXCL4) and activation 
of an inducible Irf8/β-catenin progenitor self-renewal network controls the transient 
formation of regenerating GMP clusters. In leukemia, we show that GMP clusters are 
constantly produced due to persistent activation of the self-renewal network and lack of 
termination cytokines that normally restore stem cell quiescence. Our results uncover a 
previously unrecognized dynamic behavior of GMPs in situ, which tunes emergency 
myelopoiesis and is hijacked in leukemia.  
Our understanding of blood production has evolved considerably over the past years, 
mainly due to the introduction of new technologies to study hematopoietic stem cell (HSC) 
biology both in situ in their BM niche and at the clonal level. Recent lineage tracking approaches 
in native conditions, as opposed to transplantation experiments, have uncovered a prominent role 
for multipotent progenitors (MPP) in maintaining blood production1,2. Detailed functional studies 
of the MPP compartment have identified three functionally distinct MPP subsets (MPP2, MPP3, 
MPP4) with unique lineage preferences that work together to adjust blood production to the need 
of the organism3,4. In particular, the increased production of myeloid-biased MPP2/3 by HSCs 
and the myeloid reprogramming of lymphoid-biased MPP4 are now emerging as one of the first 
steps of regenerative myelopoiesis4. 
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Myelopoiesis has long been considered to progress with the orderly differentiation of 
MPPs into uncommitted common myeloid progenitors (CMP), which then produce lineage-
committed granulocyte/macrophage progenitors (GMP) and megakaryocyte/erythrocyte 
progenitors (MEP)5. This idea is now being challenged by results of single-cell RNA-Seq 
approaches6,7 and more refined barcoding lineage tracking experiments8 indicating pre-existing 
lineage specifications in CMPs, and a large degree of molecular and functional heterogeneity in 
all myeloid progenitor (MP) populations. However, our knowledge of MP biology still lacks a 
precise understanding of how myeloid differentiation occurs spatially in the BM cavity. Here, we 
used imaging approaches similar to the ones that recently illuminated many important features of 
HSCs and their niches9-11, to provide new insights into the mechanisms by which the BM niche 
microenvironment controls myelopoiesis.  
Imaging GMPs in situ 
We took advantage of the phenotypic characteristics of GMPs (Lin-/c-Kit+/Sca-1-
/FcγR+/CD34+)5 to design an immunofluorescence (IF) staining scheme allowing their specific 
recognition on isolated populations and bone sections (Extended Data Fig. 1a). In wild type 
(WT) mice, GMPs were found scattered throughout the BM cavity with no particular distribution 
in relation to the bone endosteum, trabecular regions or central marrow, and were usually 
identified as individual cells intermingled with other hematopoietic populations (Fig. 1a). In 
contrast, in models of myeloproliferative neoplasm (MPN) such as Scl-tTA::TRE-BCR/ABL 
(BA)12 and junBflox/flox::MORE-Cre (jB)13 mice, most GMPs were found as part of large, compact 
clusters surrounded by lineage positive cells (Fig. 1b, Extended Data Fig. 1b, c). This process 
was progressive and directly associated with disease development, starting with loose GMP 
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patches (pGMP) that evolved into large, compact GMP clusters (cGMP) (Extended Data Fig. 
1d). We defined pGMPs as the collection of ≥ 4-6 GMPs loosely associated together, which 
could also be occasionally observed at steady state in WT mice, and distinguished them from 
cGMPs by the fact that they were not tightly surrounded by mature lineage cells (Extended Data 
Fig. 1e). While GMPs were never found in WT spleens, we observed abundant cGMPs in the 
disorganized red pulp of BA and jB mice (Extended Data Fig. 2a). Similar features were 
observed in the MLL-AF9 (MF9) transplanted model of acute myeloid leukemia (AML)14, with 
structures ranging from loose pGMPs to large, compact cGMPs depending on the recipient mice 
(Extended Data Fig. 2b). Using a simplified version of this IF scheme, we investigated whether 
cGMP formation was associated with a major re-organization of the BM microenvironment, but 
found no obvious changes in blood vessel network, hypoxia level, or deposition of extracellular 
matrix (ECM) components, except for collagen IV as expected for the fibrotic BA BM niche15 
(Extended Data Fig. 2c). We also tracked the localization of mature populations in relation to 
cGMPs, and while some lymphoid cells were detected inside and at the periphery of cGMPs, 
myeloid cells were only found tightly surrounding cGMPs (Extended Data Fig. 2d). These 
results indicate that leukemic myelopoiesis is characterized by the presence of cGMPs, which are 
part of a continuum of differentiation separating progenitors from mature myeloid cells. 
GMP clusters are a feature of myeloid expansion 
To determine whether cGMPs could be detected during emergency myelopoiesis, we 
used several models of myeloid regeneration or active myeloid cell production. First, WT mice 
were injected once with 5-fluorouracil (5-FU; 150 mg/kg) and followed for myeloid regeneration 
over time (Fig. 1c). Flow cytometry analyses showed increased numbers of immature Lin-/c-
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Kit+/Sca-1+ (LSK) cells by d10, which essentially reflected increased production of myeloid-
biased MPP2/3 by 5-FU-activated HSCs (Fig. 1d, Extended Data Fig. 3a, b). In contrast, GMP 
numbers were reduced by d8 and reverted to steady state levels by d10, while granulocyte (Gr) 
numbers sharply decreased by d8, and then slowly recovered to exceed steady state levels by 
d14. Strikingly, IF staining of 5-FU BM showed rare GMPs at d8, followed by the appearance of 
pGMPs by d8.5, which quickly expanded in size up to d10 when the first cGMPs where observed 
(Fig. 1e, Extended Data Fig. 3c). By d12, we only found cGMPs, particularly along the bone 
endosteum, which then had completely disappeared by d14 upon Gr restoration. We observed 
similar transient cGMP formation in WT mice injected once with Ly-6G antibody (0.1 
mg/mouse) to specifically ablate Grs16, or daily with G-CSF (5 µg/mouse) to increase Gr 
production17 (Extended Data Fig. 4a, b). We also confirmed transient cGMP formation during 
the peak of myeloid regeneration following HSC transplantation, when both myeloid-biased 
MPP2/3 and GMPs were specifically expanded4 (Extended Data Fig. 4c). Moreover, we 
demonstrated that cGMPs were predominantly clonal and composed of GMPs derived from 
individual HSCs-MPP2/3 undergoing regenerative or leukemic myelopoiesis (Supplemental 
Information, Extended Data Fig. 5, a-d). Collectively, these results indicate that transient cGMP 
formation is a hallmark characteristic of emergency myelopoiesis. 
GMP clusters are foci of myeloid differentiation 
To understand the mechanisms of cGMP formation, we conducted detailed cell cycle 
analyses by injecting BrdU or EdU into 5-FU-treated WT mice (Fig. 2a, b, Extended Data Fig. 
6a). In LSKs, BrdU incorporation peaked at d8 and then progressively reverted to steady state 
levels by d12. In GMPs, BrdU incorporation first increased at d8, at the onset of pGMP 
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formation, and then dropped below steady state levels between d10-12 when pGMPs turned into 
cGMPs, before reverting to steady state levels by d14 when cGMPs had disappeared. This 
pattern was reflected in IF staining, with proliferating EdU+ pGMPs observed at d10, and cGMPs 
markedly devoid of proliferating EdU+ cells compared to their surroundings at d12. In contrast, 
the number of dividing phospho-histone H3 (pH3) positive MPs was not significantly different 
between cGMPs and their surroundings at d10-12, although they appeared preferentially located 
along the edges of the clusters (Fig. 2b). Similar analyses performed in BA mice did not uncover 
altered GMP proliferation rates, and emphasized the preferential distribution of pH3+ dividing 
cells along the edges of the clusters (Fig. 2c, d). Close examination of cGMP periphery in BA 
mice highlighted a clear differentiation gradient, with reciprocal expression patterns for FcγR 
and lineage markers in GMPs undergoing differentiation across the cluster boundary defined by 
c-Kit expression (Fig. 2e). Single cell clonogenic methylcellulose analyses of GMPs isolated 
from 5-FU-treated WT mice confirmed a change in differentiation potential associated with 
cGMP formation, with increased plating efficiency and immature GM colonies at d8-10, 
followed by restoration of low GM frequency and a significant loss of M colonies at d12-14 (Fig. 
2f). Finally, we confirmed that mature myeloid cells also directly surrounded cGMPs in 5-FU-
treated mice (Extended Data Fig. 6b). Collectively, these results uncover complex changes in the 
cellular behavior of GMPs associated with cluster formation, with increased proliferation and 
immaturity in expanding pGMPs that form the cGMPs, followed by a sharp block in 
proliferation and restoration of differentiation potential in differentiating cGMPs that divide to 
produce mature Grs. They also indicate that these features of cGMPs as foci of differentiation are 
conserved during leukemic myelopoiesis. 
Molecular reprograming in GMP clusters 
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To gain insights into the molecular mechanism controlling cGMP formation, we 
investigated pools of 100 GMPs isolated from 5-FU-treated WT mice using a custom-made 
Fluidigm PCR array platform (Supplementary Table 1). Principal component (PC) and t-
distributed stochastic neighbor embedding (tSNE) analyses of the 59 most robustly expressed 
genes revealed two distinct groups, with d8 and most d10 samples (group I) being clearly 
separated from d0 and d12-14 samples (group II) (Fig. 3a). Examination of individual genes 
highlighted signatures of activated cell cycle and strong molecular immaturity in expanding 
pGMPs (group I), which were completely reverted in differentiating cGMPs (group II) (Fig. 3b, 
Extended Data Fig. 7a-c). In particular, expanding pGMPs showed increased expression of pro-
proliferation genes including Ccne1 (cyclin E1) and Hoxa9, decreased expression of myeloid 
determinants like Irf8 and Jun/Fos (AP-1), and severely repressed expression of myeloid 
cytokine receptors (CSFR), particularly Csf1r (M-CSFR), Csf3r (G-CSFR) and Il6ra (IL-6R). 
Similar investigations performed on leukemic GMPs revealed that both BA and jB GMPs had a 
molecular signature of expanding pGMPs, with increased Ccne1 expression and decreased levels 
of Irf8, Csf1r and Il6ra (Fig. 3c, Extended Data Fig. 7d, Supplementary Table 2). To investigate 
global transcriptional changes in these conditions, we also performed single cell RNA-Seq on 
GMPs isolated from 5-FU-treated WT mice, BA and age-matched control mice. PC analysis and 
hierarchical clustering of all single GMPs using highly variable genes showed a similar picture to 
our targeted Fluidigm gene expression analyses (Extended Data Fig. 7e), with the identification 
of two major clusters that were used to compare the expression profiles of d8 vs. d0 5-FU GMPs 
and BA vs. control GMPs (Fig. 3d, Supplementary Table 3, 4). Remarkably, d0 and control 
GMPs showed high expression of the previously defined group II genes and reflected steady 
state GMPs (ssGMPs), whereas d8 and BA GMPs were characterized by expression of group II 
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genes and coincided with self-renewing GMPs (srGMPs). Allocation to each cluster of all single 
GMPs across the 5-FU kinetics and in BA mice showed the presence of 8.5 to 13.5% srGMPs at 
steady state, and persistence of ~ 15% ssGMPs at d8 and the peak of self-renewing GMP patches 
(Fig. 3e). Together, these results uncover significant molecular reprogramming during cGMP 
formation, characterized by cell cycle activation and suppression of maturation pathways in 
expanding pGMPs, followed by cell cycle blockade and re-activation of maturation pathways in 
differentiating cGMPs. They also indicate that leukemic GMPs are molecularly primed for 
cGMP formation. Moreover, they demonstrate the co-existence of distinct steady state and self-
renewing GMPs in both normal and leukemic contexts, in proportions that reflect the activation 
state of emergency myelopoiesis. 
GMP self-renewal network 
We next probed the function of the key myeloid transcription factor Irf8[18] in cGMP 
formation. Irf8-/- mice are immunodeficient and develop MPN over time19. Similar to BA and jB 
mice, we observed constitutive cGMP formation in the BM of primary or transplanted Irf8-/- 
mice (Fig. 4a, Extended Data Fig. 8a-c), which demonstrate that decreasing Irf8 expression is 
enough to drive cGMP formation. We also found delayed cGMP formation kinetics in 5-FU-
treated primary and transplanted Irf8-/- mice, which, in turn, indicate that restoration of Irf8 
expression is essential for cGMP differentiation, likely for increasing the expression of CSFR 
genes like Csf1r that is a direct Irf8 target20. Interestingly, Irf8 and Ctnnb1 (β-catenin) are part of 
an antagonistic regulatory network in chronic myelogenous leukemia (CML)21, and activated β-
catenin signaling provides aberrant self-renewal features to leukemic GMPs in both CML and 
AML contexts22,23. Strikingly, we observed increased nuclear β-catenin in d8 regenerating 
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GMPs, and in both BA and jB GMPs (Fig. 4b, c). However, downregulation of Irf8 did not 
directly drive β-catenin as neither Irf8-/- GMPs nor HSCs or MPPs showed increased nuclear β-
catenin (Fig. 4d, Extended Data Fig. 8d). In contrast, GMPs from Ctnnb1 gain-of-function 
(GOF) and loss-of-function (LOF) mice had decreased and increased Irf8 expression, 
respectively, leading to the presence of pGMPs at steady state in Ctnnb1 GOF mice, and 
unchanged steady state levels but significantly delayed cGMP formation upon 5-FU treatment in 
Ctnnb1 LOF mice (Fig. 4e-g, Extended Data Fig 8e, f). Collectively, these results place Irf8 and 
β-catenin at the center of an inducible self-renewal progenitor network controlling cGMP 
formation, with β-catenin directly suppressing Irf8 expression and Irf8 eventually re-enforcing β-
catenin expression in MPN contexts (Fig. 4h). 
BM niche signals control GMP cluster formation 
To identify the environmental factors involved in cGMP formation, we performed ELISA 
analyses on BM fluid from 5-FU treated WT mice (Fig. 5a). Interestingly, we found significantly 
elevated levels of cytokines known to stimulate HSC proliferation and trigger myeloid 
differentiation, like SCF and G-CSF, prior to pGMP expansion (d5-8), and factors important for 
restoring HSC quiescence, like TGF-β1 and CXCL4 (PF4), at the time of cGMP formation (d10-
12)24. In contrast, we observed no changes in the level of the BM homing chemokine CXCL12 
(SDF1α) and a surprising decrease, rather than the reported increase25, in FGF1 production 
(Extended Data Fig. 9a). G-CSF and IL-1 are both produced by the damage vasculature in stress 
conditions26,27. Close examination by IF staining confirmed significant vascular damage 
following 5-FU treatment, with major gaps between dysmorphic laminin+ ECs leading to 
vascular leakage into the stromal microenvironment, especially at d8-10 when pGMPs were 
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expanding (Fig. 5b, Extended Data Fig. 9b). To address the role of G-CSF, we injected it for 4 
consecutive days in 5-FU-treated WT mice either from d1-4 (early injections) prior to pGMP 
expansion, or from d8-11 (late injections) during the cGMP differentiation period (Fig. 5c, 
Extended Data Fig. 9c). Strikingly, early G-CSF injections significantly accelerated cGMP 
formation, while late G-CSF injections significantly amplified and extended the period of cGMP 
formation. We recently reported impaired myeloid regeneration in 5-FU-treated Il1r1-/- mice, and 
showed that IL-1 trigger regenerative myelopoiesis by activating PU.1 in HSCs26. Consistently, 
we observed significantly delayed cGMP formation in 5-FU-treated Il1r1-/- mice, and 
constitutive cGMP formation at steady state in IL-1-treated WT mice (Fig. 5d, Extended Data 
Fig. 9d). TGF-β1 and CXCL4 are both produced by megakaryocytes (Meg), which are important 
components of the HSC niche28,29. Interestingly, IF staining showed an overabundance of large, 
mature CD150+ Megs in close association with cGMPs in every tested regenerative context, 
including 5-FU, G-CSF and Ly-6G treatments (Fig. 5e, Extended Data Fig. 9e). To address the 
role of Megs in secreting quiescence-enforcing signals, we used a previously published 
diphtheria toxin (DT)-based approach to delete Megs in 5-FU-treated Cxcl4-Cre::iDtr mice28 
(Fig. 5f, Extended Data Fig 9f). Strikingly, Megs depletion lead to persisting cGMP formation 
during the Gr outburst period past d14, massive reduction in CXCL4 and TGF-β1 production, 
and prevention of HSC return to quiescence (Fig 5f-h, Extended Data Fig. 9g). Collectively, 
these findings demonstrate that many distinct and temporally regulated BM niche signals are 
important for various aspects of cGMP formation (Fig. 6a). This includes the early production of 
SCF and IL-1, which activate HSCs to produce MPP2/3 and initiate emergency myelopoiesis. It 
is followed by the production of G-CSF that dictates when self-renewing pGMPs are formed, 
likely by triggering the Irf8/β-catenin progenitor self-renewal network and engaging the whole 
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process of cGMP formation and associated Gr outburst. Finally, it is terminated by the late 
production of TGF-β1 and CXCL4 by Megs surrounding cGMPs, which re-establish HSC 
quiescence and limit the duration of the regenerative response. 
Deregulated GMP cluster formation in leukemia 
To understand why cGMP formation is constitutively activated in leukemia, we 
performed similar ELISA analyses on BM fluid from BA and jB mice (Fig. 6b, Extended Data 
Fig. 10a). Strikingly, we found a consistent decrease in quiescence-enforcing cytokines in both 
MPN models, with undetectable levels of TGF-β1 and CXCL4 in BA mice, and significantly 
reduced TGF-β1 production in jB mice. IF staining revealed decreased numbers of CD150+ 
Megs in close proximity of cGMPs in both MPN models, ranging from almost absent in BA 
mice to infrequent in jB mice (Fig. 6c). QRT-PCR analyses further confirmed reduced Cxcl4 
expression from BA Megs (Extended Data Fig. 10b). Moreover, IF staining of laminin+ blood 
vessels indicated constitutively damaged ECs with high vascular leakage in both MPN models 
(Fig. 6c, Extended Data Fig. 10c). We also observed the persistence of very large cGMPs 
associated with constant Gr overproduction in 5-FU-treated BA mice (Fig. 6d, Extended Data 
Fig. 10d). These results indicate that transformed HSC-derived leukemic stem cells (LSC) 
continuously produce cGMPs as a direct consequence of high levels of activating cytokines, like 
IL-1, produced by the inflamed leukemic BM niche12. This, in turn, results in the overproduction 
of MPP2/3[15], which are committed to form pGMPs likely due to the constitutive activation of 
the self-renewal Irf8/β-catenin network by the driving oncogenes, rather than by extrinsic 
myeloid cytokines. Most importantly, this activation process never stops because essential 
quiescence-enforcing cytokines such as TGF-β1 and CXCL4 are missing due to the loss or 
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insufficient production of leukemic Megs. Altogether, these results demonstrate that the 
leukemic BM niche is both constitutively activated and lacking important feedback mechanisms, 
thereby driving constant cGMP formation and Gr production (Fig. 6e). 
Discussion 
Our results expand the understanding of myeloid progenitor biology, and report a novel 
and highly dynamic in situ behavior of GMPs that for the first time link changes in their 
molecular and cellular functions with spatial organization in the BM niche. They identify two 
new functional states for GMPs, with self-renewing pGMPs building GMP clusters, and 
differentiating cGMPs producing mature myeloid cells until complete disappearance of the GMP 
clusters. This biphasic process is a transient feature of emergency myelopoiesis, and is highly 
controlled by the timed released of BM niche signals. These findings, together with the recent 
identification of myeloid-biased MPP2/3[4], help construct a revised map of emergency 
myelopoiesis pathways and a deeper understanding of their hijacking in leukemia (Extended 
Data Fig. 10e). They also provide an explanation for the recently reported molecular 
heterogeneity in GMPs6,7,30, with the co-existence in variable proportions of distinct steady state 
and self-renewing GMPs, and are essential for interpreting the results of lineage tracking 
experiments showing major contributions of MPPs and MPs to myeloid output1,2. Moreover, our 
results identify several new mechanisms that could be harnessed for translational applications. 
Pathological investigations have reported the presence of immature myeloid cell aggregates in 
bones of leukemic patients30, including clusters of proliferating myeloblasts surrounded by TGF-
β-producing Megs31, which could represent similar aberrant cGMP formation in humans. Future 
studies will address whether targeting various regulators of cGMP formation could be used to 
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prevent the development of myeloid malignancies or, conversely, to boost myeloid cell 
production in myelosuppressed conditions. 
Full Methods and any associated references are in the accompanying supplementary information 
document. 
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Figure Legends 
Figure 1 | GMP clusters in leukemic and regenerative myelopoiesis. a, b, Representative IF 
staining showing GMPs (purple) in the BM of (a) wild type (WT), and (b) diseased Scl-tTA:TRE-
BCR/ABL (BA) mice. Solid lines indicate bone surface, dotted lines cGMPs and arrowheads 
individual GMPs. c, PB and BM regeneration in 5-FU-treated WT mice. d, Changes in 
hematopoietic populations at the indicated days post 5-FU treatment. e, Representative IF 
staining showing GMPs (purple) in the BM of 5-FU -treated mice. Stars indicate pGMPs and 
dotted lines cGMPs. Results are expressed as mean ± S.D. (grey bars, reference range); **p < 
0.01, ***p < 0.001. 
Figure 2 | GMP clusters are foci of differentiation. a, Proliferation in 5-FU-treated WT mice 
showing experimental scheme and BrdU incorporation in LSKs and GMPs (n = 3). b, 
Representative IF staining showing MPs (red) in relation to proliferating EdU+ (green, upper 
row) and dividing pH3+ (green, lower row) cells in 5-FU-treated BM. c, BrdU incorporation in 
GMPs from Ctrl and BA mice (n = 3). d, Representative IF staining showing MPs (red) in 
relation to proliferating EdU+ (green, upper row) and dividing pH3+ (green, lower row) cells in 
Ctrl and BA BM. e, Representative IF staining of GMP cluster periphery (dotted lines) 
highlighting differentiating GMPs (arrows) as they lose FcγR expression and gain lineage marker 
expression. f, Single-cell clonogenic methylcellulose analyses of GMPs isolated from 5-FU-
treated WT mice (n = 4; *, vs. plating efficiency; •, vs. GM colonies; °, vs. M colonies). Colonies 
were scored after 7 days. Pictures show representative colonies and results are expressed as 
percent colony type at each time point. GM: granulocyte/macrophage, Gr: granulocyte, and M: 
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macrophage, colonies. Stars indicate pGMPs and dotted lines cGMPs. Results are expressed as 
mean ± S.D. (grey bars, reference range); *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
Figure 3 | Molecular mechanisms of GMP cluster formation. a, tSNE analyses of Fluidigm 
gene expression data from GMPs isolated from 5-FU-treated WT mice (n = 2; 10-16 pools of 
100 cells/condition). b, Selected genes from Fluidigm analyses shown in (a). Results are 
expressed as fold change compared to levels in d0 GMPs and presented as boxplots (line: 
median; box: 25th and 75th percentiles; whisker: 90th and 10th percentiles). c, Selected genes from 
Fluidigm analyses of GMPs isolated from BA, jB and respective age-matched Ctrl mice (n = 4; 
22-28 pools of 100 cells/condition). Results are expressed as fold change compared to levels in 
respective Ctrl GMPs and presented as in (b). d, PC analyses of single cell RNA-Seq data from 
GMPs isolated from 5-FU-treated WT mice (476 single cells) and BA mice (306 single cells). e, 
frequency of steady state GMP (ssGMP) and self-renewing GMPs (srGMP) in 5-FU-treated WT 
mice, and Ctrl and BA mice. *p ≤ 0.05; **p ≤ 0.01, ***p ≤ 0.001. 
Figure 4 | Irf8/β-catenin self-renewal progenitor network. a, Representative IF staining of 
GMPs (purple) in 5-FU-treated Irf8+/+ and Irf8-/- BM. b-d, Nuclear β-catenin in (b) GMPs from 
d8 5-FU-treated WT mice with representative negative (-) and positive (+) staining shown for d0 
GMPs, (c) GMPs from BA, jB and respective age-matched Ctrl mice, and (d) GMPs from Irf8+/+ 
and Irf8-/- mice. Results are expressed as percent positive cells. e, Irf8 expression in GMPs from 
Ctnnb1 gain-of-function (GOF) and loss-of-function (LOF) mice. f, Representative IF staining of 
GMPs (purple) in Ctnnb1 Ctrl and GOF BM. g, Representative IF staining of GMPs (purple) in 
5-FU-treated Ctnnb1 Ctrl and LOF BM. h, Model of the molecular network controlling pGMP 
self-renewal (SR) and cGMP differentiation (diff.). Red indicates activation and green 
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suppression, with dotted line highlighting re-enforcing pathways in MPNs. Stars indicate pGMPs 
and dotted lines cGMPs. Results are expressed as mean ± S.D. (grey bars, reference range); *p ≤ 
0.05; **p ≤ 0.01, ***p ≤ 0.001. 
Figure 5 | BM niche controls of GMP cluster formation during regenerative myelopoiesis. 
a, ELISA cytokine measurements in BM fluids of 5-FU-treated WT mice (n = 3). b, 
Representative IF staining showing vasculature (blue, pseudo-colored in yellow in magnified 
inserts) and vascular leakage (green, dragon green (DG) microsphere diffusion assay) in 5-FU-
treated BM. c, Representative IF staining showing GMPs (purple) in 5-FU-treated BM, with or 
without concomitant daily injections of G-CSF (+G) on d1-4. d, Representative IF staining of 
GMPs (purple) in Il1r1+/+ and Il1r1-/- 5-FU-treated BM, or BM of IL-1β-injected WT mice. e, 
Representative IF staining showing CD150+ megakaryocytes (red) in 5-FU- and G-CSF-treated 
WT BM. f-h, Megakaryocyte depletion studies in diphtheria toxin (DT) injected iDtr (Ctrl) and 
Cxcl4-Cre:iDtr (Cre) mice, and non-injected Ctrl mice [(-)DT]: (f) experimental scheme and 
representative IF staining of GMPs (purple) in 5-FU-treated BM, (g) ELISA cytokine 
measurements in BM fluids at d10 (n = 3) and d12 (n = 4), and (h) HSC cell cycle distribution at 
d12 (n = 3). Stars indicate pGMPs and dotted lines cGMPs. Results are expressed as mean ± S.D. 
(grey bars, reference range); *p ≤ 0.05; **p ≤ 0.01, ***p ≤ 0.001. 
Figure 6 | Continuous GMP cluster formation in leukemic myelopoiesis. a, Model of 
regenerative myelopoiesis. EC: endothelial cells; MSC: mesenchymal stromal cells; Meg: 
megakaryocytes; Comm.: commitment; SR: self-renewal; Diff.: differentiation. Red indicates 
activation and green suppression. b, ELISA cytokine measurements in BM fluids of diseased 
BA, jB and respective Ctrl mice (n = 3). c, Representative IF staining showing CD150+ 
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megakaryocytes (red), vasculature (blue, pseudo-colored in yellow in magnified inserts) and 
vascular leakage (green, DG microsphere diffusion assay) in BA, jB and respective Ctrl BM. d, 
Representative IF staining of GMPs (purple) 5-FU-treated Ctrl and BA BM. e, Model of 
leukemic myelopoiesis. LSC: leukemia-initiating stem cells. Stars indicate pGMPs and dotted 
lines cGMPs. Results are expressed as mean ± S.D.; *p ≤ 0.05. 
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Online Methods 
Mice. Six- to 12-week-old C57Bl/6-CD45.2 wild type mice were used as donor for cell isolation 
and in vivo treatments. Eight- to 12-week old C57Bl/6-CD45.1 (Boy/J) wild type mice were used 
as recipients for cell transplantation experiments. C57Bl/6-CD45.2 Scl-tTA::TRE-BCR/ABL 
(BA)12, junBflox/flox::MORE-Cre (jB)13, Irf8-/-19, Il-1r1-/-33, Csf1r-Gfp34, ß-actin-Gfp35, Ctnnb1 
Flox(Ex3) (GOF)36, Ctnnb1flox/flox (LOF)37, Mx1-Cre38, Cxcl4-Cre39 and iDtr40 mice were used 
for bone harvest and in vivo treatments at various ages. Bones from control and MLL-AF9 
transplanted mice14 shipped overnight (O/N) from Dr. Armstrong’s laboratory (MSKCC, NY) 
were immediately used upon delivery. BA mice were bred in the presence of 20 mg/L 
doxycycline (Sigma-Aldrich, D9891-10G) in their drinking water, and induced for CML-like 
MPN development by doxycycline withdrawal at 5 weeks of age. Recipient mice were irradiated 
at a lethal dose of 1100 rad delivered in split doses 3 hours apart using a Cs137 source (J.L. 
Shepherd). BM cells were injected in a volume of 100 µl into the retro-orbital plexus 
immediately after irradiation, and transplanted mice were treated with antibiotics for 4 weeks 
post-irradiation. Peripheral blood was obtained from retro-orbital bleeding, and either collected 
in tubes containing 4 ml of ACK (150 mM NH4Cl/10 mM KHCO3) containing 10 mM EDTA for 
flow cytometry analyses, or in EDTA-coated microtainer tubes (Beckton-Dickenson) for 
complete blood counts (CBC) using an Hemavet hematology system (Drew Scientific). BM 
cellularity was determined using a ViCell automated cell counter (Beckman-Coulter). For 5-FU 
treatments, mice were injected intraperitoneally (i.p.) once with 150 mg/kg 5-FU (Sigma-
Aldrich, F6627-5G) or PBS control. All 5-FU-injected mice were screened for efficient 
myeloablation by CBC analyses and BM cellularity measurement. For Ly-6G treatment, mice 
were injected i.p. once with 0.1 mg of anti-Ly-6G or rat-IgG control antibodies (UCSF 
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Hybridoma Core Facility). For G-CSF treatments, mice received daily i.p. injections of 5 µg G-
CSF (Neupogen) or PBS control. For Mx1-Cre-mediated deletion, mice were injected i.p. three 
times 2 days apart with 250 µg of poly(I/C) (pIC, GE Healthcare) in 200 µl PBS. For IL-1β 
treatments, mice received daily i.p. injections of 0.5 µg IL-1β (Peprotech) or PBS/0.2% BSA 
control. For megakaryocyte depletion, mice received daily i.p. injections of 250 ng diphtheria 
toxin (List Biological Laboratories, 150) or PBS control. Megakaryocytes depletion was 
confirmed by CBC analyses and IF staining. For proliferation analyses, mice were injected once 
i.p. with either BrdU (Sigma-Aldrich, B5002-5G) or EdU (Thermo Fisher Scientific, A00144) 1 
hour prior to sacrifice. For pimonidazol staining, mice were injected with 60 mg/kg 
pimonidazole-HCl (Hypoxyprobe, HP2-100Kit) and sacrificed 1 hour later. For investigations of 
blood vessel integrity, mice were injected with 50 µl of dragon green (DG) microspheres (Bangs 
Laboratories, FS02F/10597) 10 min prior sacrificing and immediately perfused with 10 ml PBS 
by cardiac puncture before bone harvest as described41. No specific randomization or blinding 
protocol was used, mouse of both genders were utilized, and all experiments were performed in 
accordance with UCSF IACUC approved protocols.. 
Flow cytometry. BM stem and progenitor populations were analyzed and/or isolated as 
previously described4. In brief, BM cells were obtained by either crushing leg, arm and pelvic 
bones or just flushing leg bones in Hanks’ Buffered Saline Solution (HBSS) containing 2% heat-
inactivated FBS (Sigma-Aldrich). HBSS/2% FBS was used for all incubation and wash steps. 
Erythrocytes and contaminating bone material were removed by ACK lysis followed by 
centrifugation on a Ficoll gradient (Histopaque 1119, Sigma-Aldrich) for crushed bones. For cell 
analyses, unfractionated BM cells were incubated with purified, unconjugated-lineage antibodies 
(CD3 from Biolegend, and CD4, CD5, CD8, B220, Ter119, Mac-1 and Gr-1 from eBioscience) 
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followed by goat anti-rat-PE-Cy5 (Invitrogen, A10691) and subsequently blocked with purified 
rat IgG (Sigma-Aldrich, I8015-10MG). Cells were then stained with c-Kit-APC-eFluor780 
(eBioscience, 47-1171-82), Sca-1-PB (BioLegend, 108120), CD48-A647 (BioLegend, 103416), 
CD150-PE (BioLegend, 115904) and either CD34-FITC (eBioscience, 11-0341-85) together 
with FcγR-PerCP-eFluor710 (eBioscience, 46-0161-82) for combined stem/progenitor staining 
or only ESAM-FITC (Biolegend, 136205) for detailed analyses of HSC and MPP2/3 after 5-FU 
treatment. For Csf1r-Gfp mice, CD34-FITC was replaced by CD34-Bio (Biolegend, 119304) 
followed by staining with SA-PeCy7 (eBioscience, 25-4317-82). For GMP sorting, BM cells 
were first pre-enriched for c-Kit+ cells using c-Kit microbeads (Miltenyi Biotec, 130-091-224) 
and MACS Separation LS Columns (Miltenyi Biotec, 130-042-401), and stained as described 
with Lin/PE-Cy5, c-Kit-APC-eFluor780, Sca-1-PB, CD34-FITC and FcγR-PerCP-eFluor710. 
For mature cell analyses, unfractionated BM cells were stained with Mac-1-PE-Cy7 
(eBioscience, 25-0112-82), Gr-1-PB (eBioscience, 57-5931-82), B220-APC-Cy7 (eBioscience, 
47-0452-82) and CD19-PE (eBioscience, 12-0193-82). Peripheral blood cells were stained with 
Mac-1-PE-Cy7, Gr-1-PB, B220-APC-Cy7, CD3-APC (eBioscience, 17-0032-82) and Ter-119-
PE-Cy5 (eBioscience, 15-5921-83), with either co-detection of GFP or addition of CD45.1-FITC 
(eBioscience, 11-0454-85) and CD45.2-PE (eBioscience, 12-0453) for analyses of chimeric 
mice. Stained cells were finally re-suspended in HBSS/2% FBS containing 1 µg/ml propidium 
iodide (PI) for dead cell exclusion, and either sorted on a FACS ARIAII or analyzed on a LSRII 
using DIVA software (Becton Dickinson). GMPs were double sorted to ensure maximum purity. 
For intracellular BrdU and Ki67/DAPI staining, BM cells were first stained as above, then fixed 
in Cytofix/Cytoperm buffer (BD Biosciences, 554714) for 10 min (BrdU) or 30 min 
(Ki67/DAPI) in the dark, washed in PermWash (BD Biosciences), permeabilized with CytoPerm 
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Plus (BD Biosciences) for 10 min at room temperature (RT), re-fixed in Cytofix/Cytoperm 
buffer for 5 min in the dark and washed in PermWash. For BrdU staining, cells were then treated 
with 0.5 U/µl DNAseI in 3% BSA/0.2x PBS/5mM MgCl2/2mM CaCl2 for 30 min at RT in the 
dark, washed in PermWash, stained with FITC-conjugated anti-BrdU (347583, BD Biosciences) 
for 30 min at RT, washed in PermWash, and re-suspended in HBSS/2% FBS. For Ki67/DAPI 
staining, cells were then stained with anti-Ki67 antibody (eBioscience, 11-5698-80) for 1 hour at 
RT in the dark, washed in PermWash and re-suspended in HBSS/2% FBS containing DAPI at 
1µg/ml (Sigma-Aldrich, 32670). In both cases, cells were analyzed on a FACS LSR II as 
described above. 
Immunofluorescence on tissue sections. Mouse femurs or spleens were snap frozen in OCT 
(Tissue-Tek) and kept at -80C until sectioning. Frozen samples were cryosectioned (7µm) using 
a Cryostat equipped with the Cryojane tape transfer system and tungsten blades (Leica 
Microsystems). Sections were dried for 2-4 hours at RT and then frozen at -80°C until stained. 
Prior staining, sections were fixed with 100% acetone for 10 min at -20°C, dried for 5 min at RT 
and blocked for 1 hour 30 min at RT with 10% goat-serum (Gibco) in PBS. For regular GMP 
staining, sections were incubated first with rat anti-mouse c-Kit (Biolegend, 135102) primary 
antibody O/N at 4°C in PBS/10% goat-serum, followed with a goat anti-rat-Cy3 (Jackson 
Immunoresearch, 112-165-167) secondary antibody for 1 hour at RT in PBS/10% goat-serum 
and washed 3x for 5 min with PBS at RT. These wash steps were also performed between each 
staining steps. Sections were then blocked with 20 µg/ml Rat IgG (Sigma-Aldrich, I8015-10MG) 
for 10 min at RT in PBS, and finally stained with A488-conjugated lineage markers (B220 from 
Invitrogen, and Mac-1, Gr-1 and CD3 from Biolegend), Sca-1-A488 (Biolegend, 108116), 
CD150-A488 (Biolegend, 115916) and FcγR-A647 (UCSF Hybridoma Core Facility) for 1 hour 
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30 min at RT in PBS/10% goat-serum. For GMP staining of the MLL-AF9 transplantation 
model, the eBioscience mouse hematopoietic lineage biotin panel (88-7774), Sca-1-bio 
(eBioscience, 13-5981-1630), and CD150-bio (Biolegend, 115908) were used instead of A488-
conjugated antibodies followed by staining with a SA-e450 (eBioscience, 48-4317) antibody. For 
laminin and GMP co-staining, FcγR was omitted and rabbit anti-mouse laminin (Sigma-Aldrich, 
L9393) followed by staining with a goat anti-rabbit-A647 secondary antibody was used instead. 
For the other GMP co-staining, A647-conjugated lineage antibodies (Biolegend, B220, Mac-1, 
Gr-1 and CD3), Sca-1-A647 (Biolegend, 108118) and CD150-A647 (Biolegend, 115918) were 
used instead of A488-conjugated antibodies, and FcγR was omitted. For laminin and ECM 
protein co-detection, rabbit anti-mouse laminin, Collagen IV (Abcam, ab6586) and fibronectin 
(Abcam, ab23750) were used followed by staining with a donkey anti-rabbit-A488 (Sigma-
Aldrich, A-21206) secondary antibody. For clonality analyses, either CD45.2-FITC (Biolegend, 
109816) or A488-conjugated anti-GFP (Aves labs, GFP-1020) were used. For laminin and DG-
microsphere co-staining, sections were just stained with rabbit anti-mouse laminin followed by 
goat anti-rabbit-A647. For proliferation analyses, either pH3-FITC (Cell Signaling, 9708S) or 
Click-iT® EdU Alexa Fluor® 488 Imaging Kit (ThermoFisher Scientific, C10337) were used 
according to the manufacturer’s instructions. For myeloid/lymphoid cells and GMP co-staining, 
FcγR, CD150 and Sca-1 were omitted and B220-A488 (Invitrogen, RM2620), CD3-A488 
(Biolegend, 100210), Gr-1-A647 (Biolegend, 108418) and Mac-1-A647 (Biolegend, 101218) 
were used instead. For megakaryocytes and GMP co-staining, FcγR was omitted and rat anti-
mouse CD150 (Biolegend, 115902) followed by staining with a goat anti-rat-Cy3 secondary 
antibody was used instead. For cleaved caspase 3 (CC3) and GMP co-staining, FcγR was omitted 
and sections were fixed for 10 min with 4% PFA at RT then washed 3x for 5 min at RT in 
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PBS/0.1% triton X100. Sections were first incubated with a rabbit anti-CC3 (Cell Signaling, 
9661-S) antibody followed by a goat anti-rabbit-A647 (Thermo Fisher Scientific, A-21245) 
secondary antibody, and then stained as usual for c-Kit and A488-conjugated lineage. For 
pimonidazol staining, frozen sections were fixed with 4% PFA for 10 min at RT and stained with 
FITC-conjugated anti-pimonidazole (Hypoxyprobe, HP2-100Kit) according to the 
manufacturer’s instructions. After staining, all sections were counterstained with 1 µg/ml DAPI 
in PBS for 10 min at RT, mounted with fluoromount (Southern Biotech, 0100-01) and imaged on 
a SP5 upright or SP8 inverted confocal microscopes (Leica) with a 20x objective. Images were 
processed using Volocity software (Perkin Elmer v.6.2) and analyzed with ImageJ. The analyze 
particle function and a threshold mask covering laminin+ cells was also used in ImageJ to 
quantify DG-microsphere mean intensity fluorescence (MFI) outside of blood vessels.  
Immunofluorescence on purified cells. GMP (2,000 cells/slide) were directly sorted onto poly-
lysine coated slides (Sigma-Aldrich, P0425-72EA) and let settle down for 15 min at RT. Cells 
were washed 3x for 5 min with PBS at RT between each staining step. For GMP re-stain, cells 
were fixed with 100% acetone for 5 min at -20°C, blocked for 1 hour 30 min at RT with 
PBS/10% goat-serum and stained as described above for regular GMP staining on sections. For 
β-catenin staining, cells were fixed with 4% PFA for 10 min at RT, and then permeabilized and 
blocked with PBS/0.1% Tween-20/10% FBS for 1 hour at RT. Cells were then stained with a 
rabbit anti-mouse β-catenin (Cell Signaling, 9582S) primary antibody O/N at 4°C in PBS/0.1% 
Tween-20/10% FBS, followed by an anti-rabbit-A555 (Invitrogen, A31572) secondary antibody 
for 1 hour at RT in PBS/0.1% Tween-20/10% FBS. Slides were mounted with VectaShield 
(Vector Laboratories, H-1200) containing 1 µg/ml DAPI and imaged on a SP5 upright confocal 
 28 
microscope (Leica) with a 20x objective. Images were processed using Volocity software and an 
average of 390 individual cells were scored per condition for nuclear β-catenin quantification. 
In vitro analyses. All cultures were performed at 37°C in a 5% CO2 water jacket incubator 
(Thermo Scientific). For clonogenic methylcellulose colony assays, GMPs (1 cell/well) were 
directly sorted into 96-well plates containing 100 µl methylcellulose (Stem Cell Technologies, 
M3231) supplemented with the following cytokines (all from PeproTech): IL-3 (10 ng/ml), GM-
CSF (10 ng/ml), SCF (10 ng/ml), IL-11 (10 ng/ml), Flt-3L (10 ng/ml), Tpo (100 ng/ml) and Epo 
(4 U/ml). Colonies were visually scored after 7 days of culture. For apoptosis assays, GMPs (400 
cells/well) were directly sorted into 384-well solid white luminescence plates containing 40 µl 
Iscove’s modified Dulbecco’s media (IMDM) supplemented with 5% FBS (StemCell 
Technology, 06200), 1x penicillin/streptomycin, 0.1 mM non-essential amino acids, 1 mM 
sodium pyruvate, 2 mM L-glutamine and 50 µM 2-mercaptoethanol. Immediately after sorting, 
40 µl of Caspase-Glo 3/7 (Promega) was added to each well, shaken for 30 second at 300 r.p.m., 
incubated for 45 min at RT and read on a luminometer (Synergy2, BioTek) to obtain relative 
luciferase units (RLU). 
Fluidigm analyses. Gene expression analyses using the Fluidigm 96.96 Dynamic Array IFC 
were performed as previously described4,12. Briefly, GMPs (100 cells/well) were directly sorted 
into 96 well-plates containing CellsDirect lysis buffer (Invitrogen, 11753-100), reverse-
transcribed and pre-amplified for 18 cycles using Superscript III Platinum Taq DNA polymerase 
(Invitrogen, 18080-044) using a custom-made set of 96 proprietary target-specific primers 
(Fluidigm). The resulting cDNAs were analyzed on a Biomark system (Fluidigm) using 
EvaGreen Sybr dye (Bio-Rad, 172-5211). Data were collected using Biomark Data Collection 
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Software (Fluidigm) and analyzed using Biomark qPCR analysis software with a quality 
threshold of 0.65 and linear baseline correction. Identical settings used across all experiments 
performed on different 96.96 dynamic arrays. Melt curves and Tm values for each assay reaction 
were checked individually, and reactions with melt curves showing multiple peaks or poor 
quality (<0.65) were discarded, leaving 60 genes and 2 housekeeping genes (Gusb and Gapdh) 
for further analyses. For gene expression quantification, data were exported as an Excel .csv file 
and analyzed by the ΔΔCt method using Gusb (5-FU GMPs) or Gapdh (MPN GMPs) for 
normalization as previously described (Reynaud et al., 2011). tSNE and PC analyses were 
performed as previously described4 on the 59 (5-FU GMPs) and 35 (MPN GMPs) most robustly 
expressed genes following quality control assessment, and normalized to Gapdh.  
Single cell RNA-Seq. Single GMPs were directly sorted into individual wells of a 96-well PCR 
plate containing 2.3 µl of 0.2% Triton-X100 (Sigma-Aldrich, 93443) and 2.3 U of SUPERase-In 
RNase Inhibitor (Ambion, AM2694). cDNA was obtained and amplified following the described 
SMARTSEQ2 protocol42. Libraries were prepared for sequencing from 125 ng of cDNA using 
the Illumina Nextera XT DNA preparation kit. Pooled libraries were run on the Illumina HiSeq 
2500 (5FU samples) or Illumina HiSeq 4000 (BA samples). Reads were mapped to the Mus 
musculus genome (Ensembl GRCm38.81) and the ERCC sequences using GSNAP (version 
2015-09-29) with –B 5 (batch mode 5) –n 1 (maximum pathsallowed: 1) -Q (if maximum paths 
more than n, not print) –N 1 (look for novel splicing). HTseq-count was used to count the 
number of reads mapped to each gene with -s no (non-strand specific mode)43. For further 
analyses, we only retained samples that had (1) more than 100,000 reads mapped to nuclear 
mRNAs, (2) more than 4,000 highly detectable genes (defined as genes with more than 10 reads 
per million), and (3) less than 20% of mapped reads allocated to mitochondrial genes. The data 
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were normalized for sequencing depth using the package scran from R Bioconductor. Highly 
variable genes were identified as described44, using a false discovery rate threshold equal to 0.1. 
Only highly variable genes were considered to perform PC analysis, using the prcomp command 
in R. Hierarchical clustering was performed using highly variable genes to identify ssGMPs and 
srGMPs. The pairwise Spearman correlation coefficients (ρ) were calculated between the 
expression levels of highly variable genes in each pair of cells. The dissimilarity matrix was then 
calculated as (1 − ρ)/2. Hierarchical clustering was performed using the default 'complete' 
method on the dissimilarity matrix. Identification of cells contained in each of the two clusters 
(corresponding to ssGMPs and srGMPs) was done using the cutree method with k=2 (2 groups). 
Genes differentially expressed (DE) between ssGMP and srGMP clusters were identified using 
DESeq2 (version 1.12.2)45 and only DE genes having a fold change significantly greater than 1.5 
with a false discovery rate threshold less than 0.1 were used for hierarchical clustering.  
qRT-PCR. For megakaryocytes enrichment, flushed BM cells were filtered through a 100µm 
mesh filter and sedimented 30 min at RT through a gradient of 1.5 to 3% BSA, with 
megakaryocytes pelleting at the bottom of the 3% BSA gradient. Total RNA was isolated from 
3x104 cells re-suspended in Trizol LS (Life Technologies, 10296-010) according to the 
manufacturer’s protocol. For qRT-PCR, RNA was treated with DNaseI and reverse-transcribed 
using SuperScript III kit and random hexamers (Life Technologies, 18080-051). Runs were 
performed on a 7900HT Fast Real-Time PCR system (Applied Biosystems) using SybrGreen 
reagents (Kapa Biosystems, KK4603) and the cDNA equivalent of 200 cells per reaction. 
Sequences for qRT-PCR primers were: Cxcl4, (S) TCTCCTCTGGGATCCATCTT, (AS) 
CATTCTTCAGGGTGGCTATGA (NM_019932); β-actin, (S) 
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GACGGCCAGGTCATCACTATTG, (AS) AGGAAGGCTGGAAAAGAGCC (NM_007393). 
Values were normalized to β-actin expression levels. 
Cytokine ELISA. For collecting BM fluids, the four long bones (two femurs and two tibiae) of 
each mouse were flushed with the same 200 µl of HBSS/2% FBS using a 0.3cc insulin syringe 
with a 28g needle and spun at 500 × g for 5 min to remove BM cells. Supernatants were further 
clarified by spinning down at 12,000 × g for 10 min, and samples were subsequently stored at -
80°C until use. For ELISA measurements, 4x-diluted (SCF, CXCL12, FGF1), 5x-diluted (TGF-
β1), 20x-diluted (G-CSF) and 1000x-diluted (PF4) samples were analyzed according to the 
manufacturer's instructions (Raybiotech for SCF, G-CSF, PF4 and CXCL12; R&D Systems for 
TGF-β1) or as previously described for FGF125. 
Statistics. All experiments were repeated as indicated. N indicates the numbers of independent 
biological repeats. Numbers of independent experiments are reported in the supplementary data. 
Data were expressed as means ± standard deviation (S.D.) except when indicated. Statistical 
analyses were performed using Prism 5.0 software (GraphPad). Pairwise statistical significance 
was evaluated by two-tailed Mann-Whitney u-test or paired Student’s t-test. Mice for treatment 
and transplantation were randomized, and no blinding protocol was used. No statistical method 
was used to predetermine sample size. P-values ≤ 0.05 were considered statistically significant. 
Data availability. Datasets that support the findings of this study have been deposited online 
with the GEO accession numbers GSE90799. 
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Extended Dataset 
Myeloid progenitor cluster formation drives emergency and leukemic myelopoiesis. 
Hérault, A., Binnewies, M., Leong, S., Calero-Nieto, F.J., Zhang, S.Y., Kang, Y-A., Wang, X., 
Pietras, E.M., Chu, S.H., Barry-Holson, K., Armstrong, S., Göttgens, B. & Passegué, E. 
 
Extended Data Fig. 1 | Imaging GMPs in normal and leukemic conditions. a, Gating strategy 
used to identify GMPs showing representative FACS plots with purified GMPs (purple) stained 
with IF markers, and a representative WT GMP (purple circle) on bone section. b, Inducible Scl-
tTA::TRE-BCR/ABL (BA) and constitutive junBflox/flox::MORE-Cre (jB) mouse models of human 
MPN with representative GMP FACS plots. Ctrl: control; Dox: doxycycline. c, Representative 
IF staining showing GMPs (purple) in the BM of diseased jB mice. d, Progression of cGMP 
 2 
formation with disease development in BA mice at the indicated weeks (wks) post-dox 
withdrawal. e, Representative examples of loose pGMPs and compact cGMPs in WT and BA 
mice. Solid lines indicate bone surface, dotted lines cGMPs and stars pGMPs. 
 
Extended Data Fig. 2 | GMP cluster features. a, Representative IF staining of GMPs (purple) 
in WT and diseased BA and jB spleens. b, cGMPs in recipient mice developing AML following 
transplantation of MLL-AF9 (MF9) transduced LSK-derived cells. Experimental scheme and 
representative IF staining of GMPs (purple) in control (Ctrl) and diseased MF9 recipient BM. 
Three individual recipient mice are shown for MF9. c, Representative IF staining showing MPs 
(red) in relation to the indicated stromal features (green) in Ctrl and diseased BA BM. d, 
Representative IF staining showing MPs (red) in relation to mature lymphoid (green) and 
myeloid (blue) cells in Ctrl and diseased BA BM. Dotted lines indicate cGMPs; i and ii highlight 
two magnified areas. Orange lines indicate germinal centers, arrowheads individual GMPs, stars 
pGMPs and dotted lines cGMPs. 
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Extended Data Fig. 3 | Regenerating BM following 5-FU treatment. a, Gating strategy used 
to identify the indicated BM populations by flow cytometry in 5-FU-treated WT mice. 
Representative FACS plots are shown at the indicated days post-treatment. b, Frequency of BM 
LSK, HSC, MPP2/3, GMP and Gr at the indicated days post-5-FU treatment. c, Representative 
IF staining showing GMPs (purple) in 5-FU treated BM at the indicated days post-treatment. 
Solid lines indicate bone surface and dotted lines cGMPs. Results are expressed as mean ± S.D. 
(grey bars, reference range); *p ≤ 0.05, **p < 0.01, ***p < 0.001.  
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Extended Data Fig. 4 | GMP clusters during myeloid regeneration and expansion. a, Gr 
depletion in the BM of Ly-6G-treated mice with experimental scheme and representative FACS 
plots and IF staining of GMPs (purple) at the indicated days post-treatment. b, Gr expansion in 
the BM of G-CSF-treated mice with experimental scheme and representative FACS plots and IF 
staining of GMPs (purple) at the indicated days post-treatment. c, GMP clusters in the BM of 
HSC-transplanted mice with experimental scheme and representative IF staining of GMPs 
(purple) at the indicated weeks (wks) post-transplantation. Non-transplanted WT BM is shown 
for comparison. Dotted lines indicate cGMPs and stars pGMPs. 
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Extended Data Fig. 5 | GMP clusters are clonal. a-c, Clonality of regenerative GMP clusters: 
(a) Percent CD45.2+ cells in the peripheral blood (PB) pre- and BM post-5-FU treatment for each 
of the chimera mice used at the indicated days post-treatment (n = 2-3 mice/group); (b) 
Representative IF staining showing MPs (red) and CD45.2 (green) expression in 5-FU-treated 
chimera BM at the indicated days post-treatment; and (c) experimental scheme and 
representative IF staining showing MPs (red) and CD45.2 (green) expression separately in two 
independent d12 5-FU-treated chimera BM. Positive (+) clusters have ≥ 75% CD45.2+ cells and 
negative (-) clusters ≤ 5% CD45.2+ cells. Wks: weeks. d, Clonality of leukemic GMP clusters 
with experimental scheme and representative IF staining showing MPs (red) and GFP (green) 
expression from β-actin-Gfp cells in diseased BA chimera BM. Positive (+) clusters have ≥ 75% 
GFP+ cells and negative (-) clusters ≤ 5% GFP+ cells. Dotted lines indicate cGMPs. 
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Extended Data Fig. 6 | Dynamic proliferation and differentiation in regenerating GMP 
clusters. a, Representative FACS plots showing kinetics of BrdU incorporation in LSKs and 
GMPs from 5-FU-treated WT mice at the indicated days post-treatment. b, Representative IF 
staining showing MPs (red) in relation to mature lymphoid (green) and myeloid (blue) cells in 5-
FU BM at the indicated days post-treatment. 
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Extended Data Fig. 7 | Molecular reprogramming in regenerating and leukemic GMP 
clusters. a, Additional Fluidigm gene expression analyses of regenerating GMPs isolated from 
5-FU-treated WT mice at the indicated days post-treatment (n = 2; 10-16 pools of 100 
cells/condition). Results are expressed as fold change compared to levels in untreated (D0) 
GMPs and presented as boxplots (line: median; box: 25th and 75th percentiles; whisker: 90th and 
10th percentiles). b, Loading association of principal component (PC) analyses of Fluidigm gene 
expression data from regenerating GMPs. c, Representative FACS plots of GFP expression in 
GMPs of 5-FU-treated Csf1r-Gfp reporter mice at the indicated days post-treatment. d, tSNE 
analyses and loading association of PC analyses of Fluidigm gene expression data from MPN 
GMPs isolated from diseased BA, jB and respective age-matched Ctrl mice (n = 4; 22-28 pools 
of 100 cells/condition). e, PC analyses of single cell GMP RNA-Seq data showing the 
distribution of each 5-FU time points (D0: 89 cells; D8: 187 cells; D10: 89 cells; D12: 75 cells; 
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D14: 36 cells) and individual Ctrl (94 cells) and BA (BA(1): 68 cells; BA(2): 57 cells; BA(3): 87 
cells) mice.  
 
 
Extended Data Fig. 8 | Irf8 and β-catenin function in self-renewing GMPs. a, Representative 
FACS plots showing GMPs and Grs at steady state in Irf8+/+ and Irf8-/- mice. b, Experimental 
scheme for Irf8+/+ and Irf8-/- BM chimeric mice. c, Representative IF staining of donor-derived 
CD45.2+ (green) MP (red) in 5-FU-treated Irf8+/+ and Irf8-/- BM chimeric mice. d, Nuclear β-
catenin in HSCs, MPP3 and MPP4 from Irf8+/+ and Irf8-/- mice. Results are expressed as percent 
positive cells. e, f, Experimental scheme for Ctnnb1 Ctrl and Ctnnb1 (e) loss-of-function (LOF) 
or (f) gain-of-function (GOF) mice. Stars indicate pGMPs and dotted lines cGMPs. Results are 
expressed as mean ± S.D. 
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Extended Data Fig. 9 | Mechanisms controlling GMP cluster formation during 
regeneration. a, ELISA measurement of cytokine levels in BM fluids of 5-FU-treated WT mice 
at the indicated days post-treatment (n = 3). b, Quantification of vascular leakage in 5-FU-treated 
BM at the indicated days post-treatment (n = 3). Results are expressed as dragon green (DG) 
microsphere MFI upon masking of laminin+ blood vessels. c, Representative IF staining showing 
GMPs (purple) in 5-FU-treated BM with concomitant daily injections of G-CSF (+G) on d8-11. 
d, Investigation of 5-FU-treated Il1r1+/+ and Il1r1-/- mice at the indicated days post-treatment 
showing representative IF staining of GMPs (purple), FACS plots of Gr regeneration, and 
quantification of the indicated BM populations (3-4 mice/group). e, Representative IF staining of 
CD150+ megakaryocytes (red) in 5-FU- and Ly-6G-treated BM. f, g, Megakaryocyte depletion 
studies in diphtheria toxin (DT) injected iDtr (Ctrl) and Cxcl4-Cre:iDtr (Cre) mice showing (f) 
representative IF staining of CD150+ megakaryocytes (red) at the indicated days post-5-FU, and 
(g) representative Ki67/DAPI staining of HSCs at d12 post-5-FU. Stars indicate pGMPs and 
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dotted lines cGMPs. Results are expressed as mean ± S.D. (grey bars, reference range); *p ≤ 
0.05; **p ≤ 0.01, ***p ≤ 0.001. 
 
 
Extended Data Fig. 10 | Deregulated GMP cluster formation in leukemic mice. a, ELISA 
measurements of cytokine levels in BM fluids of BA, jB and respective Ctrl mice (n = 3). b, 
qRT-PCR measurement of Cxcl4 expression in BM and Meg-enriched BSA gradient of Ctrl and 
BA mice (3 mice/group). c, Quantification of vascular leakage in diseased BA, jB and respective 
Ctrl BM (3-4 mice/group). Results are quantified as dragon green (DG) microsphere MFI upon 
masking of laminin+ blood vessels. d, Representative FACS plots showing Gr regeneration in 5-
FU-treated Ctrl and BA mice at the indicated days post-treatment. e, Revised model of 
emergency myelopoiesis. At steady state, blood production reflects the differential generation by 
HSCs of a small number of myeloid-biased MPP2/3 and a large number of lymphoid-biased 
MPP4, which both give rise to GMPs and contribute to myeloid output. In contrast, in emergency 
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situations, HSCs are induced to overproduce MPP2/3, and MPP4 are reprogrammed towards 
almost exclusive myeloid output in large part due to cytokine stimulations and the triggering of 
specific regulatory pathways. An important consequence of the activation of this myeloid 
regeneration axis is the generation of localized pGMP/cGMP differentiation foci in the BM 
cavity, which drive the overproduction of granulocytes. This entire process is tightly regulated 
by BM niche signals and is transient during emergency myelopoiesis, but is constantly activated 
in myeloid leukemia. Important emerging questions are what controls the switch from self-
renewing (SR) pGMP to differentiating (diff.) cGMP clusters, if expanded MPP2/3 and myeloid-
reprogrammed MPP4 also generate pGMP/cGMPs or continue to produce regular GMPs (dotted 
lines), and whether Grs produced through this regeneration axis functionally differ from steady 
state Grs (heterogeneity). Results are expressed as mean ± SD; *p ≤ 0.05, ***p ≤ 0.001. 
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Supplementary Information 
Myeloid progenitor cluster formation drives emergency and leukemic myelopoiesis. 
Hérault, A., Binnewies, M., Leong, S., Calero-Nieto, F.J., Zhang, S.Y., Kang, Y-A, Wang, X., 
Pietras, E.M., Chu, S.H., Barry-Holson, K., Armstrong, S., Göttgens, B. & Passegué, E. 
Supplementary Table 1 | Fluidigm gene expression levels in regenerating GMPs. 
 GMP (5-FU) 
Genes            D8          D10          D12          D14 
Atrx 0.64 ± 0.13 *** 0.81 ± 0.21 * 0.99 ± 0.18 0.97 ± 0.18 
Bad 1.15 ± 0.47 1.19 ± 0.50 1.02 ± 0.37 1.13 ± 0.43 
Bak1        1.310 ± 0.26 ** 1.194 ± 0.19 * 0.989 ± 0.15 0.889 ± 0.16 
Bax 1.87 ± 0.78 * 1.56 ± 0.64 1.37 ± 0.70 1.23 ± 0.57 
Bcl2 0.60 ± 0.08 *** 0.53 ± 0.09 *** 0.72 ± 0.08 *** 0.96 ± 0.13 
Bcl2l1 0.82 ± 0.17 * 0.99 ± 0.15 1.11 ± 0.14 1.35 ± 0.17 *** 
Bcl2l11 0.86 ± 0.15 * 0.90 ± 0.19 0.94 ± 0.20 1.01 ± 0.18 
Bid 0.87 ± 0.18 0.93 ± 0.22 0.94 ± 0.24 1.14 ± 0.22 
Bmi1 0.92 ± 0.24 0.96 ± 0.30 1.06 ± 0.21 0.91 ± 0.23 
Ccna2 1.09 ± 0.19 0.82 ± 0.11 ** 0.86 ± 0.13 * 0.85 ± 0.16 * 
Ccnb1 1.06 ± 0.13 1.05 ± 0.12 0.92 ± 0.16 0.95 ± 0.25 
Ccnc 1.11 ± 0.21 1.06 ± 0.27 0.96 ± 0.17 0.94 ± 0.17 
Ccnd1 1.64 ± 0.67 ** 0.92 ± 0.37 0.61 ± 0.26 *** 0.70 ± 0.21 *** 
Ccnd2 1.11 ± 0.24 1.01 ± 0.40 0.60 ± 0.14 ** 0.62 ± 0.23 ** 
Ccnd3 1.11 ± 0.31 0.92 ± 0.22 0.82 ± 0.11 0.96 ± 0.43 
Ccne1 2.30 ± 0.74 *** 1.36 ± 0.38 *** 0.98 ± 0.19 1.06 ± 0.19 
Cd34 0.91 ± 0.17 0.64 ± 0.10 *** 0.85 ± 0.15 * 1.18 ± 0.25 * 
Cd44 0.64 ± 0.07 *** 0.84 ± 0.11 *** 0.88 ± 0.08 * 1.08 ± 0.08 
Cd48 1.12 ± 0.23 1.05 ± 0.20 1.14 ± 0.28 1.19 ± 0.23 
Cdc42 0.83 ± 0.25 1.03 ± 0.45 1.07 ± 0.37 0.94 ± 0.33 
Cdk1 0.92 ± 0.10 0.92 ± 0.16 0.91 ± 0.13 0.90 ± 0.15 * 
Cdk2 0.87 ± 0.16 0.92 ± 0.14 1.04 ± 0.22 1.10 ± 0.18 
Cdk4 1.04 ± 0.17 1.03 ± 0.12 0.97 ± 0.12 0.97 ± 0.07 
Cdkn1b 0.56 ± 0.38 ** 0.84 ± 0.74 1.21 ± 0.65 1.17 ± 0.81 
Cebpa 0.83 ± 0.15 * 0.91 ± 0.15 0.86 ± 0.13 0.96 ± 0.22 
Cish 2.58 ± 1.21 *** 1.68 ± 0.48 ** 1.34 ± 0.59 1.34 ± 0.55 
Csf1r 0.11 ± 0.02 *** 0.43 ± 0.12 *** 1.03 ± 0.17 1.54 ± 0.18 *** 
Csf3r 0.80 ± 0.14 ** 0.98 ± 0.18 1.07 ± 0.22 1.14 ± 0.29 
Egr1 0.85 ± 0.42 0.73 ± 0.64 * 1.22 ± 0.43 1.72 ± 0.54 
Evi1 1.23 ± 1.47 1.46 ± 1.41 1.15 ± 1.39 0.99 ± 1.23 
Flt3 1.23 ± 0.55 2.23 ± 1.09 * 3.26 ± 1.08 *** 2.42 ± 0.74 *** 
Fos 0.41 ± 0.12 *** 0.50 ± 0.31 *** 0.88 ± 0.23 * 1.85 ± 0.55 *** 
Foxo3 1.02 ± 0.15 1.09 ± 0.21 1.17 ± 0.36 1.24 ± 0.28 
Gata2 1.15 ± 0.32 0.83 ± 0.38 0.69 ± 0.32 * 0.55 ± 0.23 *** 
Hoxa9 2.13 ± 0.30 *** 2.50 ± 0.74 *** 1.65 ± 0.54 * 1.38 ± 0.31 
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Id2 0.35 ± 0.08 *** 1.09 ± 0.40 0.83 ± 0.27 1.05 ± 0.29 
Ikzf1 0.82 ± 0.08 ** 0.82 ± 0.14 ** 0.90 ± 0.09 0.98 ± 0.11 
Il6ra 0.29 ± 0.04 *** 0.54 ± 0.16 *** 0.97 ± 0.21 1.43 ± 0.20 *** 
Irf8 0.08 ± 0.03 *** 0.19 ± 0.14 *** 0.80 ± 0.15 1.34 ± 0.29 * 
Jun 0.36 ± 0.16 *** 0.38 ± 0.14 *** 0.60 ± 0.18 *** 1.23 ± 0.35 
Junb 1.30 ± 0.52 1.32 ± 0.34 0.93 ± 0.20 1.15 ± 0.34 
Mcl1 1.05 ± 0.14 1.17 ± 0.21 1.04 ± 0.17 1.06 ± 0.17 
Myc 1.11 ± 0.20 1.35 ± 0.42 ** 0.83 ± 0.23 ** 0.89 ± 0.22 
Notch1 0.58 ± 0.08 *** 0.56 ± 0.21 *** 1.01 ± 0.08 1.18 ± 0.09 ** 
Prkdc 0.83 ± 0.18 * 0.85 ± 0.28 0.90 ± 0.23 1.13 ± 0.17 
Pten 0.96 ± 0.10 1.00 ± 0.08 1.01 ± 0.11 1.00 ± 0.09 
Rac1 0.84 ± 0.21 0.78 ± 0.14 0.86 ± 0.15 0.99 ± 0.25 
Rad51 0.98 ± 0.20 0.86 ± 0.14 * 0.91 ± 0.18 * 1.01 ± 0.15 
Rb1 0.87 ± 0.25 0.99 ± 0.26 1.10 ± 0.30 1.19 ± 0.23 
Rpa1 1.19 ± 0.18 1.05 ± 0.14 1.00 ± 0.21 1.05 ± 0.17 
Runx1 0.72 ± 0.12 ** 0.78 ± 0.11 * 0.87 ± 0.15 1.05 ± 0.17 
Sfpi1 0.94 ± 0.22 1.04 ± 0.25 1.17 ± 0.31 1.04 ± 0.32 
Socs2 1.04 ± 0.55 1.20 ± 0.73 1.02 ± 0.71 1.66 ± 1.60 
Stat1 0.73 ± 0.08 *** 0.85 ± 0.10 ** 0.87 ± 0.17 * 1.20 ± 0.17 * 
Stat3 1.32 ± 0.43 1.61 ± 0.58 * 1.37 ± 0.40 * 1.17 ± 0.36 
Stat5a 0.91 ± 0.24 0.82 ± 0.14 * 0.93 ± 0.17 1.01 ± 0.27 
Stat5b 0.80 ± 0.14 ** 0.85 ± 0.14 1.07 ± 0.18 1.22 ± 0.20 * 
Trp53 1.07 ± 0.15 1.04 ± 0.11 1.10 ± 0.16 1.06 ± 0.13 
Xrcc5 1.25 ± 0.26 * 1.29 ± 0.36 1.23 ± 0.38 0.76 ± 0.25 ** 
Xrcc6 1.17 ± 0.17 * 1.02 ± 0.18 0.92 ± 0.14 0.95 ± 0.17 
 
GMPs isolated from 5-FU-treated WT mice at the indicated days post-treatment were used for 
Fluidigm gene expression analyses (n = 2; 10-16 pools of 100 cells/condition). (#) Indicate genes 
that were excluded from PC and tSNE analyses. Results are mean ± SD and are expressed as fold 
changes compared to levels in untreated (D0) GMPs; *p ≤ 0.05; **p ≤ 0.01, ***p ≤ 0.001. 
Supplementary Table 2 | Fluidigm gene expression levels in leukemic GMPs. 
 GMP (MPN) 
Genes            BA          jB 
Atrx 0.90 ± 0.11 ** 0.96 ± 0.15 
Bad 1.14 ± 0.33 1.29 ± 0.53 
Bak1 0.974 ± 0.15 1.178 ± 0.17 *** 
Bax 1.01 ± 0.36 1.28 ± 0.50 
Bcl2 0.62 ± 0.20 *** 0.70 ± 0.24 *** 
Bcl2l1 0.90 ± 0.15 * 1.11 ± 0.23  
Bcl2l11 0.99 ± 0.15 0.89 ± 0.21 * 
Bid 0.79 ± 0.14 *** 0.90 ± 0.19 * 
Bmi1 0.34 ± 0.07 * 0.73 ± 0.11 
Ccna2 0.85 ± 0.14 *** 0.99 ± 0.09 
Ccnb1 0.90 ± 0.22 * 1.02 ± 0.16 
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Ccnc 0.96 ± 0.12 1.10 ± 0.21 
Ccnd1 1.54 ± 1.16 0.61 ± 0.24 *** 
Ccnd2 1.01 ± 0.57 0.81 ± 0.20 *** 
Ccnd3 0.96 ± 0.25 1.16 ± 0.20 ** 
Ccne1 1.22 ± 0.35 * 1.19 ± 0.20 ** 
Ccne2 0.88 ± 0.12 ** 1.10 ± 0.24 
Cd34 0.60 ± 0.31 *** 0.88 ± 0.24 * 
Cd44 0.91 ± 0.15 * 1.05 ± 0.19 
Cd48 0.84 ± 0.18 ** 1.01 ± 0.16 
Cdc42 0.79 ± 0.15 *** 1.19 ± 0.42 
Cdk1 0.80 ± 0.14 *** 1.05 ± 0.14 
Cdk2 0.87 ± 0.17 ** 0.93 ± 0.17 
Cdk4 0.91 ± 0.11 ** 1.04 ± 0.15 
Cdkn1b 0.95 ± 0.34 0.82 ± 0.27 * 
Cebpa 1.01 ± 0.25 1.03 ± 0.16 
Cltc 0.96 ± 0.10 1.12 ± 0.18 * 
Csf1r 0.57 ± 0.13 *** 0.84 ± 0.28 * 
Csf3r 1.06 ± 0.12 1.18 ± 0.12 *** 
Ebf1 0.75 ± 0.18 *** 0.49 ± 0.18 
Egr1 2.25 ± 1.64 ** n.d. 
Flt3 3.41 ± 3.02 1.21 ± 0.54 
Fos 1.31 ± 0.63 0.70 ± 0.26 *** 
Foxo3 0.85 ± 0.17 ** 0.81 ± 0.17 *** 
Gata2 0.98 ± 0.99 * 0.56 ± 0.28 *** 
Hoxa9 1.54 ± 0.33 *** 0.53 ± 0.15  
Ikzf1 0.92 ± 0.12 * 0.97 ± 0.20 
Il6ra 0.80 ± 0.26 *** 0.80 ± 0.26 *** 
Irf8 0.44 ± 0.26 *** 0.61 ± 0.27 *** 
Jun 1.41 ± 0.75 0.60 ± 0.23 *** 
Junb 1.12 ± 0.45 n.d. 
Mcl1 0.96 ± 0.18 0.92 ± 0.13 
Myc 1.28 ± 0.36 ** 1.33 ± 0.31 *** 
Notch1 0.17 ± 0.02 ** 0.82 ± 0.20 *** 
Pgk1 1.05 ± 0.07 * 1.15 ± 0.09 *** 
Prkdc 0.86 ± 0.26 ** 0.95 ± 0.32 
Pten 0.93 ± 0.17 1.02 ± 0.15 
Rac1 0.94 ± 0.25 0.89 ± 0.11 ** 
Rad51 0.82 ± 0.19 0.79 ± 0.11 
Rb1 0.87 ± 0.29 * 0.85 ± 0.23 ** 
Rpa1 0.79 ± 0.16 *** 1.04 ± 0.12 
Runx1 0.88 ± 0.14 ** 0.91 ± 0.19 * 
Sfpi1 1.07 ± 0.28 1.21 ± 0.23 * 
Slamf1 1.01 ± 0.62 1.14 ± 1.03 
Stat1 0.62 ± 0.09 *** 1.07 ± 0.18 
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Stat3 1.57 ± 0.75 * 1.02 ± 0.39 
Stat5a 0.95 ± 0.25 0.90 ± 0.13 * 
Stat5b 0.89 ± 0.21 * 0.82 ± 0.14 *** 
Tcf3 0.92 ± 0.28 0.91 ± 0.17 * 
Trp53 0.86 ± 0.08 *** 1.06 ± 0.12 
Xrcc5 1.94 ± 0.33 *** 1.44 ± 0.51 *** 
Xrcc6 0.88 ± 0.12 *** 1.09 ± 0.17 
GMPs isolated from BA, jB and respective age-matched control (Ctrl) mice were used for 
Fluidigm gene expression analyses (n = 4; 22-28 pools of 100 cells/condition). (#) indicate genes 
that were excluded from PC analyses. Results are mean ± SD and are expressed as fold changes 
compared to levels in respective Ctrl GMPs; *p ≤ 0.05; **p ≤ 0.01, ***p ≤ 0.001. 
Supplementary Table 3 | Top differentially expressed genes in single d8 vs. d0 GMPs. 
Genes Base mean Log2 fold 
change 
LfcSE Stat P-value P-adj 
Top 50 upregulated genes 
Ifitm1 286.27 4.64 0.24 19.54 5.25E-85 2.38E-81 
Eif2s3y 23.14 5.04 0.28 17.73 2.63E-70 7.16E-67 
Gm7676 16.69 3.75 0.28 13.60 4.28E-42 8.33E-39 
Emilin2 55.57 2.71 0.23 11.55 7.09E-31 5.68E-28 
Ctla2a 22.58 4.19 0.37 11.36 6.83E-30 5.16E-27 
Gclm 87.41 1.54 0.15 10.01 1.40E-23 6.34E-21 
Mir6236 118.17 2.39 0.25 9.46 3.16E-21 1.07E-18 
Car2 63.65 3.23 0.34 9.37 7.03E-21 2.22E-18 
Nedd4 99.33 1.61 0.18 9.05 1.43E-19 3.98E-17 
Ptprcap 108.36 1.51 0.17 8.83 1.04E-18 2.40E-16 
Lysmd2 6.00 3.54 0.41 8.73 2.56E-18 5.70E-16 
Dkkl1 4.10 3.35 0.40 8.34 7.22E-17 1.31E-14 
Gm12020 18.30 1.61 0.19 8.31 9.18E-17 1.62E-14 
Muc13 99.98 1.98 0.24 8.19 2.63E-16 4.21E-14 
Ldha-ps2 3.67 2.10 0.26 8.18 2.82E-16 4.42E-14 
Kdm5d 4.87 3.35 0.41 8.16 3.31E-16 5.07E-14 
P2ry14 15.85 2.23 0.28 7.98 1.47E-15 2.05E-13 
Vamp5 36.67 2.37 0.30 7.91 2.58E-15 3.41E-13 
Dok2 6.89 3.44 0.45 7.72 1.18E-14 1.44E-12 
Serpina3g 122.10 2.21 0.29 7.65 1.95E-14 2.33E-12 
Mcoln2 4.45 2.82 0.37 7.59 3.28E-14 3.80E-12 
AA474408 35.83 2.68 0.35 7.58 3.40E-14 3.88E-12 
Plp2 5.19 2.22 0.29 7.55 4.51E-14 5.04E-12 
Adgrg1 152.95 1.82 0.24 7.45 9.09E-14 9.59E-12 
Odc1 31.46 1.51 0.21 7.20 5.91E-13 5.75E-11 
Tspan13 40.26 1.99 0.28 7.19 6.40E-13 6.18E-11 
Tnik 3.85 2.89 0.40 7.19 6.56E-13 6.29E-11 
 5 
RP23-57A17.2 3.06 1.89 0.26 7.17 7.39E-13 6.94E-11 
Ccnd1 11.71 2.63 0.37 7.15 8.45E-13 7.72E-11 
Bcat1 3.67 2.90 0.41 7.15 8.78E-13 7.91E-11 
Gata2 39.08 2.74 0.39 7.01 2.36E-12 2.02E-10 
Ipo11 30.77 1.67 0.24 7.01 2.41E-12 2.05E-10 
Mcpt8 50.60 1.94 0.28 7.00 2.54E-12 2.14E-10 
Uty 8.35 1.53 0.22 6.95 3.72E-12 3.03E-10 
RP24-223I19.6 1.93 2.27 0.33 6.88 5.79E-12 4.53E-10 
Traf4 3.83 2.95 0.43 6.83 8.50E-12 6.29E-10 
Ptger3 14.81 2.49 0.37 6.77 1.31E-11 9.42E-10 
Msi2 9.76 1.86 0.28 6.74 1.60E-11 1.13E-09 
Trp53i11 4.78 3.05 0.45 6.72 1.77E-11 1.24E-09 
Gm11814 3.13 1.88 0.28 6.71 1.97E-11 1.37E-09 
Susd1 15.46 2.16 0.32 6.68 2.45E-11 1.67E-09 
Car12 2.98 2.43 0.37 6.65 3.01E-11 2.01E-09 
Ptpn12 10.15 2.51 0.38 6.63 3.41E-11 2.26E-09 
Clec4e 26.39 1.98 0.30 6.58 4.62E-11 2.98E-09 
Homer2 3.80 2.75 0.42 6.56 5.25E-11 3.35E-09 
Spns2 17.31 2.33 0.36 6.51 7.47E-11 4.64E-09 
Kcna3 4.21 2.73 0.42 6.45 1.14E-10 6.95E-09 
Rps6ka3 30.61 1.95 0.30 6.45 1.14E-10 6.95E-09 
Xrcc5 4.87 2.79 0.43 6.42 1.36E-10 8.18E-09 
Il1r1 4.22 2.23 0.35 6.38 1.79E-10 1.05E-08 
Top 50 downregulated genes 
Sybu 5.62 -2.96 0.13 -22.99 6.34E-117 8.63E-113 
Xist 32.86 -6.39 0.32 -19.75 8.58E-87 5.84E-83 
RP24-270K7.3 3.05 -3.15 0.16 -19.36 1.63E-83 5.56E-80 
Ly6c2 959.92 -4.35 0.32 -13.67 1.43E-42 3.25E-39 
Ly86 26.65 -5.25 0.40 -13.25 4.44E-40 6.71E-37 
Ly6c1 8.50 -4.37 0.33 -13.14 1.92E-39 2.61E-36 
Tyrobp 169.32 -2.12 0.17 -12.80 1.69E-37 2.09E-34 
I830127L07Rik 85.65 -4.36 0.36 -12.11 9.46E-34 9.24E-31 
Fcer1g 234.80 -1.71 0.14 -11.84 2.38E-32 2.16E-29 
Cybb 23.08 -2.20 0.19 -11.73 8.78E-32 7.46E-29 
Irf8 107.29 -3.05 0.27 -11.09 1.42E-28 9.65E-26 
Ighm 75.59 -2.48 0.22 -11.08 1.58E-28 1.03E-25 
Fndc5 1.42 -2.77 0.26 -10.52 6.86E-26 3.89E-23 
Rgs7 1.67 -1.97 0.19 -10.52 7.21E-26 3.93E-23 
Gm3272 1.06 -2.51 0.24 -10.38 3.20E-25 1.67E-22 
Csf1r 29.73 -3.24 0.31 -10.36 3.80E-25 1.92E-22 
Tcfl5 2.58 -2.09 0.20 -10.26 1.10E-24 5.34E-22 
Elane 3874.80 -2.58 0.26 -9.93 3.00E-23 1.24E-20 
Pyhin1 15.93 -4.13 0.42 -9.76 1.61E-22 5.75E-20 
Gm5960 19.42 -3.75 0.40 -9.42 4.66E-21 1.55E-18 
Lyz2 153.36 -1.90 0.20 -9.33 1.09E-20 3.31E-18 
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Olfml2b 1.00 -3.05 0.33 -9.22 3.07E-20 8.90E-18 
RP23-3L20.6 0.65 -2.64 0.29 -9.14 5.99E-20 1.70E-17 
Apba1 1.91 -3.18 0.36 -8.83 1.01E-18 2.38E-16 
F13a1 77.80 -2.92 0.34 -8.66 4.73E-18 9.75E-16 
Ctsh 20.82 -3.46 0.41 -8.52 1.53E-17 3.10E-15 
Tifab 28.13 -3.08 0.37 -8.38 5.39E-17 1.02E-14 
Speg 1.28 -1.71 0.20 -8.35 7.02E-17 1.29E-14 
Unc93b1 89.57 -1.83 0.23 -8.07 6.97E-16 9.98E-14 
Kcng4 0.46 -2.35 0.30 -7.89 3.01E-15 3.94E-13 
Cd93 55.39 -1.71 0.22 -7.82 5.23E-15 6.71E-13 
Ccdc150 1.64 -1.66 0.22 -7.62 2.63E-14 3.08E-12 
Slpi 73.18 -2.08 0.28 -7.53 5.19E-14 5.69E-12 
Sytl5 0.87 -1.90 0.25 -7.52 5.55E-14 6.00E-12 
RP23-307L24.2 0.59 -2.29 0.31 -7.47 8.06E-14 8.57E-12 
Cd52 26.82 -1.83 0.25 -7.30 2.91E-13 2.94E-11 
Il6ra 14.76 -1.77 0.24 -7.28 3.41E-13 3.41E-11 
Mgst2 14.81 -2.48 0.34 -7.27 3.54E-13 3.52E-11 
Sat1 32.92 -1.54 0.22 -7.16 7.92E-13 7.29E-11 
Gm26619 1.40 -1.83 0.26 -6.93 4.11E-12 3.31E-10 
Igfbp5 0.82 -1.69 0.25 -6.85 7.63E-12 5.74E-10 
Clec12a 216.88 -1.63 0.24 -6.83 8.27E-12 6.19E-10 
Ms4a6c 33.38 -1.95 0.29 -6.76 1.37E-11 9.82E-10 
Smpdl3a 51.31 -1.90 0.29 -6.64 3.07E-11 2.04E-09 
Kmo 2.90 -1.95 0.30 -6.48 9.08E-11 5.59E-09 
Pld4 19.57 -2.59 0.40 -6.40 1.54E-10 9.16E-09 
1700028E10Rik 1.23 -1.73 0.27 -6.30 3.07E-10 1.71E-08 
9330159M07Rik 1.96 -1.78 0.29 -6.17 6.85E-10 3.63E-08 
Gpc1 25.65 -2.08 0.34 -6.12 9.21E-10 4.80E-08 
Gm5398 0.94 -1.63 0.27 -6.10 1.04E-09 5.25E-08 
GMPs isolated from 5-FU-treated WT mice were used for single cell RNA-Seq analyses. 
DESEq2 results for the top 50 most upregulated and downregulated genes with at least 1.5-fold 
change in expression are shown. 
Supplementary Table 4 | Top differentially expressed genes in single BA vs. control GMPs. 
Genes Base mean Log2 fold 
change 
LfcSE Stat P-value P-adj 
Top 50 upregulated genes 
Wfdc21 106.74 5.83 0.27 21.32 7.12E-101 4.21E-97 
Eif2s3y 70.28 7.21 0.37 19.36 1.68E-83 6.61E-80 
Ddx3y 34.55 6.20 0.38 16.33 6.34E-60 1.07E-56 
Gstm1 1663.92 1.50 0.10 15.43 1.06E-53 1.57E-50 
Uty 20.81 5.46 0.40 13.81 2.11E-43 1.92E-40 
S100a8 695.69 3.85 0.28 13.61 3.65E-42 3.08E-39 
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Ccno 20.60 5.08 0.40 12.56 3.57E-36 2.81E-33 
Rpl3 220.79 1.63 0.14 11.56 6.47E-31 4.03E-28 
Slc28a2 246.89 2.43 0.22 11.11 1.07E-28 5.50E-26 
Pglyrp1 303.69 2.82 0.26 11.00 3.72E-28 1.83E-25 
Chil3 493.40 4.04 0.38 10.68 1.33E-26 5.41E-24 
Cfap57 16.65 4.43 0.42 10.58 3.61E-26 1.42E-23 
Lcn2 297.90 2.70 0.26 10.56 4.75E-26 1.81E-23 
Fcnb 226.34 3.45 0.33 10.50 8.23E-26 3.04E-23 
Tmx4 468.09 1.56 0.15 10.30 7.27E-25 2.39E-22 
Pde4d 361.89 1.82 0.18 10.16 3.08E-24 9.85E-22 
Rgcc 592.42 1.57 0.16 10.11 4.93E-24 1.53E-21 
S100a9 45.44 3.86 0.39 9.90 4.22E-23 1.25E-20 
B4galt6 181.36 2.18 0.22 9.76 1.62E-22 4.57E-20 
Maff 4.21 3.59 0.38 9.55 1.24E-21 3.20E-19 
Mgst2 296.32 1.61 0.17 9.38 6.44E-21 1.52E-18 
Chd7 160.01 2.31 0.25 9.30 1.39E-20 3.16E-18 
Gfi1 174.37 2.44 0.26 9.28 1.66E-20 3.69E-18 
Trem3 437.28 1.54 0.17 9.27 1.83E-20 4.00E-18 
Prom1 96.25 3.10 0.34 9.22 2.97E-20 6.39E-18 
Far2 201.10 2.85 0.31 9.17 4.84E-20 1.02E-17 
Gm14085 88.66 2.88 0.32 9.09 1.03E-19 2.07E-17 
Gm11505 24.38 1.56 0.18 8.90 5.38E-19 1.04E-16 
Mt2 10.91 3.63 0.41 8.83 1.08E-18 1.93E-16 
Acpp 25.68 3.56 0.41 8.79 1.51E-18 2.66E-16 
Clec4a2 207.59 2.63 0.30 8.71 2.96E-18 4.93E-16 
Prkcb 71.85 2.84 0.33 8.62 6.81E-18 1.06E-15 
Prss57 665.20 1.52 0.18 8.61 7.36E-18 1.13E-15 
Pisd-ps1 21.41 1.62 0.19 8.60 7.64E-18 1.16E-15 
Apobec3 257.63 1.54 0.18 8.60 8.16E-18 1.22E-15 
Ypel5 189.30 1.74 0.20 8.59 8.69E-18 1.28E-15 
Gm27252 39.44 3.12 0.37 8.53 1.49E-17 2.10E-15 
Fam101b 107.15 2.33 0.27 8.52 1.65E-17 2.30E-15 
Ankrd28 256.56 1.53 0.18 8.49 2.13E-17 2.92E-15 
Kdm5d 12.14 3.69 0.44 8.45 3.03E-17 4.03E-15 
Clu 25.15 3.32 0.39 8.42 3.81E-17 4.96E-15 
Sgms2 256.39 1.69 0.20 8.29 1.10E-16 1.40E-14 
Gjb3 13.87 3.52 0.44 8.01 1.13E-15 1.28E-13 
Hsd11b1 165.37 1.95 0.25 7.76 8.46E-15 8.85E-13 
9030619P08Rik 37.15 2.16 0.28 7.69 1.43E-14 1.41E-12 
Ptprr 15.67 3.15 0.41 7.67 1.77E-14 1.73E-12 
Cd63-ps 275.57 1.85 0.24 7.64 2.17E-14 2.09E-12 
Serpine2 249.93 1.97 0.26 7.57 3.82E-14 3.55E-12 
Lrg1 35.99 3.06 0.41 7.49 6.91E-14 6.29E-12 
Cd63 301.23 1.83 0.25 7.45 9.20E-14 8.19E-12 
Top 50 downregulated genes 
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Gm28438 6.97 -5.10 0.21 -24.79 1.24E-135 1.46E-131 
Lgals1 852.40 -2.30 0.13 -17.83 3.95E-71 9.35E-68 
RP23-76J15.3 2.17 -3.84 0.22 -17.25 1.08E-66 2.14E-63 
Irf8 535.80 -4.14 0.33 -12.37 3.99E-35 2.95E-32 
Gm3788 11.53 -1.68 0.15 -11.15 7.31E-29 3.93E-26 
Tpm4 29.73 -4.34 0.40 -10.85 2.00E-27 9.09E-25 
Tmsb10 21.01 -1.55 0.14 -10.72 8.58E-27 3.62E-24 
Selplg 420.21 -1.53 0.15 -10.46 1.28E-25 4.60E-23 
Gm9844 5.44 -1.81 0.17 -10.42 1.91E-25 6.65E-23 
Pyhin1 85.86 -3.76 0.38 -9.86 5.96E-23 1.72E-20 
Ighm 300.84 -3.33 0.34 -9.70 2.90E-22 7.98E-20 
Txndc5 189.90 -2.65 0.30 -8.89 6.13E-19 1.17E-16 
Cd34 283.38 -2.44 0.28 -8.85 8.47E-19 1.57E-16 
Tmem109 34.81 -3.57 0.41 -8.72 2.80E-18 4.79E-16 
Klf4 9.21 -3.75 0.43 -8.72 2.84E-18 4.80E-16 
Pfpl 0.99 -2.89 0.33 -8.69 3.61E-18 5.93E-16 
Abcb1b 8.09 -3.35 0.39 -8.57 1.01E-17 1.47E-15 
S100a10 114.42 -2.54 0.30 -8.53 1.49E-17 2.10E-15 
Rasa4 88.29 -2.85 0.34 -8.43 3.44E-17 4.52E-15 
Ass1 32.54 -2.12 0.25 -8.34 7.43E-17 9.55E-15 
Il6st 47.33 -3.13 0.38 -8.23 1.82E-16 2.27E-14 
Gm5424 84.79 -2.15 0.27 -8.08 6.48E-16 7.59E-14 
Milr1 83.60 -2.54 0.32 -8.02 1.05E-15 1.21E-13 
Gm7862 3.60 -1.80 0.23 -7.74 9.71E-15 9.90E-13 
Gm8666 2.43 -1.87 0.24 -7.71 1.27E-14 1.27E-12 
Itga1 17.95 -3.17 0.41 -7.64 2.24E-14 2.14E-12 
Ms4a6c 119.58 -1.87 0.25 -7.63 2.37E-14 2.25E-12 
Ifitm3 122.09 -1.82 0.24 -7.58 3.35E-14 3.14E-12 
Pld4 84.63 -2.89 0.39 -7.44 1.01E-13 8.88E-12 
C1galt1c1 116.48 -2.13 0.29 -7.34 2.15E-13 1.77E-11 
Esyt1 173.00 -1.76 0.24 -7.20 6.02E-13 4.66E-11 
Ctsc 182.33 -1.89 0.26 -7.20 6.08E-13 4.67E-11 
Ctsh 127.67 -2.47 0.35 -7.16 7.92E-13 6.00E-11 
Ly86 158.11 -2.71 0.38 -7.09 1.35E-12 9.84E-11 
Csf1r 189.41 -2.19 0.31 -7.03 2.09E-12 1.50E-10 
Ctss 56.13 -2.99 0.43 -7.02 2.23E-12 1.59E-10 
Met 51.31 -2.77 0.40 -6.98 2.89E-12 2.02E-10 
Nrp1 13.60 -3.08 0.44 -6.95 3.71E-12 2.51E-10 
BC094916 0.58 -2.17 0.31 -6.92 4.55E-12 3.01E-10 
Itpripl1 71.72 -2.25 0.33 -6.91 4.75E-12 3.10E-10 
Hmgn1 62.36 -1.68 0.24 -6.90 5.35E-12 3.44E-10 
Cfp 131.73 -2.17 0.32 -6.69 2.19E-11 1.34E-09 
Rassf4 144.81 -1.94 0.29 -6.63 3.32E-11 1.98E-09 
Fabp5 38.41 -1.59 0.24 -6.62 3.63E-11 2.15E-09 
Prdx4 45.81 -2.64 0.40 -6.59 4.33E-11 2.48E-09 
Apba1 13.74 -2.71 0.41 -6.56 5.22E-11 2.97E-09 
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Gm15987 4.51 -2.68 0.42 -6.42 1.37E-10 7.49E-09 
Mnda 3.08 -2.69 0.42 -6.36 2.07E-10 1.11E-08 
Ifi203 35.32 -2.30 0.36 -6.34 2.26E-10 1.20E-08 
Igsf8 25.88 -2.24 0.36 -6.24 4.46E-10 2.24E-08 
GMPs isolated from BA and age-matched Ctrl mice were used for single cell RNA-Seq analyses. 
DESEq2 results for the top 50 most upregulated and downregulated genes with at least 1.5-fold 
change in expression are shown. 
Supplementary Results 
GMP clusters are clonal. To address whether GMP clusters are the direct product of HSC-
MPP2/3 differentiation rather than a random agglomeration process, we performed clonal 
analyses in both regenerative and leukemic contexts. In a first experiment, we transplanted a 
mixture of CD45.2 and CD45.1 WT BM cells (1:3 ratio, 1.5x106/mouse) into lethally-irradiated 
CD45.1 recipients, waited 2 months for full engraftment with ~ 25% overall CD45.2 chimerism 
in every transplanted mouse, and then injected 5-FU to assess the clonality of regenerating 
CD45.2+ MP/GMP clusters by IF staining (Extended Data Fig. 5, a-c). Interestingly, post-5-FU, 
the overall level of BM CD45.2 chimerism showed considerable variation between individual 5-
FU-treated recipients during the period of GMP cluster formation, ranging from 10% to 67% at 
d12 (Extended Data Fig. 5a). Strikingly, in the low chimerism D12(b) mice virtually all 
MP/GMP clusters were considered negative for donor-derived cells (≤ 5% CD45.2+ cells), while 
in the high chimerism D12(c) mice all MP/GMP clusters were considered positive for donor-
derived cells (≥ 75% CD45.2+ cells) (Extended Data Fig. 5b, c). In a separate experiment, we 
transplanted a mixture of WT CD45.2 BM cells from β-actin-Gfp35 mice together with BA 
CD45.2 BM cells (1:1 ratio, 2x106/mouse) into lethally-irradiated CD45.1 recipients, waited 2 
months for full engraftment with ~ 50% overall GFP chimerism, and then withdrew doxycycline 
to induce BCR/ABL expression and the development within the following 2 months of a CML-
like MPN with equal contribution of both GFP+ WT and GFP- BA cells to the overproduced 
myeloid cells (Extended Data Fig. 5d)12. Remarkably, in this context, we also observed leukemic 
MP/GMP clusters that were either negative (≤ 5% GFP+ cells) or positive (≥ 75% GFP+ cells) 
but never fully mixed at 50% GFP+ cells contribution. Taken together, these results suggest that 
each cluster is predominantly clonal and composed of GMPs derived from individual 
HSCs/MPPs undergoing regenerative or leukemic myelopoiesis. 
